Cite
Response to letter to the editor 'AML and MDS associated with PARP inhibitor treatment of ovarian cancer'
MLA
David M. O’Malley, et al. “Response to Letter to the Editor ‘AML and MDS Associated with PARP Inhibitor Treatment of Ovarian Cancer.’” Gynecologic Oncology, vol. 171, Apr. 2023, pp. 164–65. EBSCOhost, https://doi.org/10.1016/j.ygyno.2023.01.033.
APA
David M. O’Malley, Jonathan A. Ledermann, & Robert L. Coleman. (2023). Response to letter to the editor “AML and MDS associated with PARP inhibitor treatment of ovarian cancer.” Gynecologic Oncology, 171, 164–165. https://doi.org/10.1016/j.ygyno.2023.01.033
Chicago
David M. O’Malley, Jonathan A. Ledermann, and Robert L. Coleman. 2023. “Response to Letter to the Editor ‘AML and MDS Associated with PARP Inhibitor Treatment of Ovarian Cancer.’” Gynecologic Oncology 171 (April): 164–65. doi:10.1016/j.ygyno.2023.01.033.